Lawmakers Clash as Mexico Moves to Criminalize Sale and Promotion of Vapes

Nov.26.2025
Lawmakers Clash as Mexico Moves to Criminalize Sale and Promotion of Vapes
Mexico’s Chamber of Deputies Health Commission has approved a bill establishing a total ban on vapes and e-cigarettes, with penalties ranging from one to eight years in prison and fines between Mex$11,000 and Mex$226,000 (USD ≈$600–$12,300). The proposal sparked controversy among opposition lawmakers, who argued that the legislation criminalizes users rather than focusing on regulation and prevention.

Key Points

 

  • Institution: Health Commission of the Chamber of Deputies (Comisión de Salud de la Cámara de Diputados)
  • Decision Date: November 2025
  • Penalties:
  1. 1–8 years in prison
  2. Fines between Mex$11,000–226,000 (≈ USD $600–$12,300)
  • Opposition Stance: Against penalizing consumers; supports regulation instead
  • Supporters’ Argument: Bill targets illegal trade, not individual users
  • Critics’ Concern: Risk of fueling black markets and criminalizing young users

 


 

2Firsts, November 26, 2025 —According to the Politica, the Health Commission of the Chamber of Deputies has approved a bill that introduces an absolute prohibition on the commercialization and promotion of vapes and electronic cigarettes across Mexico.

 

Under the proposal, those who sell or advertise such products could face between one and eight years in prison and fines ranging from Mex$11,000 to Mex$226,000 (USD ≈$600 to $12,300).

 

Opposition lawmakers strongly objected to the inclusion of criminal penalties for individuals found in possession of these products, calling it an excessive and punitive approach. They argued instead for a regulatory framework that controls sales without imprisoning consumers.

 

Ana Isabel González, a legislator from the Institutional Revolutionary Party (PRI), warned that the proposed penalties could open the door to black markets and underground sales, endangering the same youth the bill seeks to protect.

 

By contrast, Fernando Castro of the ruling Morena Party defended the bill, claiming it does not punish use or possession, but aims to protect public health and dismantle clandestine sales networks.

 

From the Citizen Movement (Movimiento Ciudadano), deputy Juan Ignacio Zavala rejected that explanation, stating that the proposal “even criminalizes buyers of e-cigarettes.”

 

“This is one of the most punitive bills to come through this chamber,” Zavala said. “That’s why Movimiento Ciudadano voted against it — it criminalizes rather than regulates.”

 

Deputy Amancay González (Movimiento Ciudadano) echoed the criticism. While acknowledging that vapes contain toxic substances and should be restricted, she condemned the measure as a ‘criminal policy against vaping’.

 

She pointed out that traffickers of hard drugs such as meth or cocaine face six years in prison, meaning the new bill would make buying a vape more punishable than selling drugs.

 

“If this passes, Mexico will become a country where it’s more dangerous to buy a vape than to traffic narcotics,” she said.

 

The bill will now advance to plenary debate in the Chamber of Deputies before moving to the Senate for potential final approval.

 

Image source: Politica

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
Reynolds Appeals ITC Defeat in Disposable Vape Section 337 Case to U.S. Federal Circuit
Reynolds Appeals ITC Defeat in Disposable Vape Section 337 Case to U.S. Federal Circuit
On March 13, 2026, R.J. Reynolds and related companies filed an appeal with the U.S. Court of Appeals for the Federal Circuit, seeking review of the U.S. International Trade Commission’s final ruling in the disposable vape Section 337 investigation.
Mar.16 by 2FIRSTS.ai
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s National School Health Survey (PeNSE) 2024 found that e-cigarette experimentation among students aged 13 to 17 rose from 16.8% in 2019 to 29.6% in 2024, while use in the previous 30 days increased from 8.6% to 26.3%. Over the same period, conventional cigarette experimentation fell from 22.6% to 18.5%, and hookah use declined from 26.9% to 16.4%.
Mar.26 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11